Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Michael, Munoz, Javier, Goy, Andre, Locke, Frederick L., Jacobson, Caron A., Hill, Brian T., Timmerman, John M., Holmes, Houston, Jaglowski, Samantha, Flinn, Ian W., McSweeney, Peter A., Miklos, David B., Pagel, John M., Kersten, Marie José, Bouabdallah, Krimo, Khanal, Rashmi, Topp, Max S., Houot, Roch, Beitinjaneh, Amer, Peng, Weimin, Fang, Xiang, Shen, Rhine R., Siddiqi, Rubina, Kloos, Ioana, Reagan, Patrick M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870225/
https://www.ncbi.nlm.nih.gov/pubmed/35658525
http://dx.doi.org/10.1200/JCO.21.02370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870225/
https://www.ncbi.nlm.nih.gov/pubmed/35658525
http://dx.doi.org/10.1200/JCO.21.02370

Ejemplares similares